Body did not reveal donation payments from Pfizer when advocating for jabs for 12-15 age group at crucial meetings, say ...

Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...

Charleston, W.Va. (WTAP) - West Virginia Attorney General Patrick Morrisey has sent letters to all of the state’s counties ...

Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive ...

Companies seeking to benefit from campaign promises to cut regulations and taxes are ditching diversity and climate ...

By Nate Raymond (Reuters) -A U.S. appeals court on Friday revived a lawsuit by a conservative group opposed to diversity ...

A federal appeals court revived a lawsuit on Friday challenging Pfizer Inc.‘s fellowship program aimed at building a diverse ...

Alzheimer’s disease could be diagnosed up to a decade earlier after the world’s biggest study of proteins is completed. The ...

Nuvalent's NVL-655 and Zidesamtinib show strong potential as first-line therapies for NSCLC. Click here to find out why I ...

H.C. Wainwright analyst Andres Maldonado keeps a Buy rating on CG Oncology (CGON) with a $75 price target after Pfizer (PFE) announced positive ...

FDA's Center for Drug Evaluation and Research director, Patrizia Cavazzoni, MD, to step down in mid-January. Other top leaders also leaving FDA.

Pfizer's Phase 3 CREST trial results highlight the efficacy of sasanlimab combined with BCG in treating high-risk non-muscle invasive bladder cancer.